PlainRecalls
FDA Drug Moderate Class II Terminated

Omnipaque (iohexol) Injection, 180mgI/mL, 20 mL Single-Dose Vial, packaged in 10 x 20 mL Vials per carton, Rx only, Distributed by GE Healthcare Inc., Marlborough, MA 01752 U.S.A.; Manufactured by GE Healthcare AS, Oslo, Norway; NDC 0407-1411-20.

Reported: December 26, 2018 Initiated: October 29, 2018 #D-0319-2019

Product Description

Omnipaque (iohexol) Injection, 180mgI/mL, 20 mL Single-Dose Vial, packaged in 10 x 20 mL Vials per carton, Rx only, Distributed by GE Healthcare Inc., Marlborough, MA 01752 U.S.A.; Manufactured by GE Healthcare AS, Oslo, Norway; NDC 0407-1411-20.

Reason for Recall

Defective Container: vial defect was identified that could potentially impact the container closure and result in a lack of sterility assurance and/or the potential for glass particles.

Details

Units Affected
1092 cartons
Distribution
TN
Location
Marlborough, MA

Frequently Asked Questions

What product was recalled?
Omnipaque (iohexol) Injection, 180mgI/mL, 20 mL Single-Dose Vial, packaged in 10 x 20 mL Vials per carton, Rx only, Distributed by GE Healthcare Inc., Marlborough, MA 01752 U.S.A.; Manufactured by GE Healthcare AS, Oslo, Norway; NDC 0407-1411-20.. Recalled by GE Healthcare Inc. Life Sciences. Units affected: 1092 cartons.
Why was this product recalled?
Defective Container: vial defect was identified that could potentially impact the container closure and result in a lack of sterility assurance and/or the potential for glass particles.
Which agency issued this recall?
This recall was issued by the FDA Drug on December 26, 2018. Severity: Moderate. Recall number: D-0319-2019.